An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc. · NCT07449702
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 240
- US sites recruiting
- 26
- Study start
- February 23, 2026
- Record last updated
- October 23, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Being studied: ORKA-001
Conditions: Plaque Psoriasis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Recruiting US locations
Oruka Therapeutics Investigative Site
Phoenix, AZ 85032
Site contact: Oruka Therapeutics Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
North Little Rock, AR 72117
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Fountain Valley, CA 92708
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Los Angeles, CA 90045
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Los Angeles, CA 90095
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
San Diego, CA 92123
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Santa Ana, CA 92701
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Santa Monica, CA 90403
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Cromwell, CT 06416
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Miami, FL 33126
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Rolling Meadows, IL 60008
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Plainfield, IN 46168
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Bowling Green, KY 42104
Site contact: Oruka Investigative Site · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Rockville, MD 20850
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Boston, MA 02111
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Detroit, MI 48202
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
New York, NY 10023
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
New York, NY 10029
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Cleveland, OH 44106
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Mason, OH 45040
Site contact: Oruka Therapeutics Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Portland, OR 97201
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Portland, OR 97210
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Frisco, TX 75033
Site contact: Oruka Therapeutics Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Houston, TX 77004
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Webster, TX 77598
Site contact: Oruka Therapeutics Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Oruka Therapeutics Investigative Site
Norfolk, VA 23502
Site contact: Oruka Investigative Site · 781-560-0299 · clinicaltrials@orukatx.com
Study contacts (from the official record)
- Oruka Clinical Trials Information · 781-560-0299 · clinicaltrials@orukatx.com
Similar studies in Arizona
All dermatology studies in Arizona →- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Phoenix, AZ + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Scottsdale, AZ + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Chandler, AZ + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Phoenix, AZ + 16 other US sites
- Eligibility basics
- Ages 18+